QuidelOrtho™

Forging the Future of Diagnostics

Financial Results 2Q 2022

August 4, 2022

Forward-Looking Statements

Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking statements in this presentation by words such as "may," "will," "would," "expect," "anticipate," "believe," "estimate," "plan," "intend," "continue," or similar words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, the benefits and results of the business combination by and among QuidelOrtho, Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc ("Ortho") and certain other entities (the "Combinations") and integration of the businesses of Quidel and Ortho, including QuidelOrtho's execution of cost and revenue synergies, commercial and other strategic goals, future financial and operating results, future plans, objectives, strategies, expectations and intentions and other statements that are not historical facts. Such statements are based on the current beliefs and expectations of QuidelOrtho's management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the Combinations; the ability to retain key employees; and other economic, business, competitive, and/or regulatory factors affecting the business of QuidelOrtho generally. Additional risks and factors are identified under "Risk Factors" in QuidelOrtho's joint proxy statement/prospectus (the "Joint Proxy Statement/Prospectus") filed with the Securities and Exchange Commission (the "Commission") on April 11, 2022 and subsequent reports filed with the Commission. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. QuidelOrtho has no obligation to update any of the forward-looking information included in this presentation, whether as a result of new information, future events, changed expectations or otherwise, except as required by law. All forward-looking statements are based on information currently available to the Company and speak only as of the date hereof.

© QuidelOrtho 2022

Supplemental Combined Financial Measures and Non-GAAP Financial Measures

Supplemental Combined Financial Measures: This presentation contains unaudited supplemental combined financial information ("Supplemental Combined Information") that gives effect to the Combinations as if Quidel and Ortho had been combined for the applicable periods. The Supplemental Combined Information presented is based on the historical financial statements of Quidel and Ortho with reclassification adjustments only and do not include all of the pro forma adjustments required under Regulation S-X Article 11 or Accounting Standards Codification 805, Business Combinations ("ASC 805"). This Supplemental Combined Information is provided for illustrative purposes only, may be updated in the future, and is not necessarily, and should not be assumed to be, indicative of the Company's expected results of operations or financial position that would have been achieved had the Combinations been completed as of the dates indicated or that may be achieved in any future period. The Supplemental Combined Information should be considered supplemental to, and not as a substitute for, pro forma financial information prepared in accordance with Regulation S-X Article 11 or ASC 805 and should be read in conjunction with the information contained in the sections entitled "The Combinations," "Management's Discussion and Analysis of Financial Condition and Results of Operations of Ortho" and "Management's Discussion and Analysis of Financial Condition and Results of Operations of Quidel" of the Joint Proxy Statement/Prospectus and the historical consolidated financial statements and related notes appearing elsewhere in, or incorporated into, the Joint Proxy Statement/Prospectus, and the Company's subsequent reports filed with the Commission. The Company's actual results of operations and financial position will differ, potentially significantly, from the Supplemental Combined Information reflected in this presentation as a result of the methodology used to prepare the Supplemental Combined Information as well as a variety of factors, including but not limited to the effect of certain expected financial benefits of the Combinations (such as revenue and cost synergies), the anticipated costs to achieve these benefits (including the cost of integration activities), tax impacts, and changes in operating results following the date of this presentation.

Non-GAAP Financial Measures: This presentation contains financial measures, including but not limited to "constant currency revenue growth," "adjusted diluted EPS," "adjusted EBITDA," "supplemental combined revenue," "supplemental combined adjusted diluted EPS," "supplemental combined adjusted EBITDA" and "supplemental combined adjusted EBITDA margin," which are considered non-GAAP financial measures under applicable rules and regulations of the Commission. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. "Adjusted EBITDA" and "adjusted diluted EPS" eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company believes that "supplemental combined revenue," "supplemental combined adjusted diluted EPS," "supplemental combined adjusted EBITDA" and "supplemental combined adjusted EBITDA margin" provide helpful Supplemental Combined Information to assist management and investors in evaluating the Company's adjusted operating results as if Quidel and Ortho had been combined for the applicable periods. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures, including the non-GAAP Supplemental Combined Information, to the most directly comparable GAAP financial measures are included in the Appendix at the end of this presentation.

© QuidelOrtho 2022

2Q 2022 Highlights[1]

- Supplemental combined revenue growth, ex-COVID-19 sales, up 9% y/y
- Double-digit growth in Point-of-Care (POC) and Molecular Diagnostics (MDx) and high-single-digit combined growth for Labs and Transfusion Medicine
- Integration is going well, and cost synergies are tracking to our annual target

Supplemental Combined Revenue
$899M[1]
+38% y/y

Supplemental Combined Adjusted EBITDA
$291M[2]
32.4% Margin

Supplemental Combined Adjusted EPS
$2.12[2]
+123% y/y

Business Unit



Geography



Category



1. Includes presentation of supplemental second quarter 2022 and 2021 revenues and adjusted operating results as if Quidel and Ortho had been combined for the applicable periods; revenue growth rates are shown on a constant currency basis; the term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using internally derived currency exchange rates held constant for each period; this additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.
2. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.

Strategic Priorities



INTEGRATION & CULTURE: Unite the people, processes and products of Quidel and Ortho to accelerate innovation, expand commercial reach and improve patient outcomes across the healthcare continuum, within a culture of speed, happiness, and engagement



PRODUCT INNOVATION: Invest in R&D to expand diagnostic testing platforms and menus across the business portfolios, and secure global clearances for roll-out of innovative instruments and assays



COMMERCIAL EXCELLENCE: Lead the industry in customer satisfaction and maximize revenue pull-through with superior quality, differentiated services and steadfast focus on Retain, Grow, Win strategies



OPERATIONAL EXCELLENCE: Integrate global operations and manage supply chains, which are expected to deliver cost synergies, competitive advantages and revenue targets



CAPITAL DEPLOYMENT: Leverage strong balance sheet and cash generation to evaluate longer-term growth investments to potentially increase operational capacity, capture a larger share of the market, and/or generate more revenue

© QuidelOrtho 2022

Integration & Culture: Progress & Next Steps

Progress-to-Date



- ✓ Issue-free close with minimal business disruption
- ✓ Stood up post-close integration program and governance structure
- ✓ Achieved 240+ critical integration milestones
- ✓ Extensive customer communications and ”white glove” global account contacts
- ✓ Activated cross-sales / cross-refer program in the U.S. – excellent response
- ✓ Developed and refined go-to-market hypotheses for international geographies
- ✓ Completed 1st post-close integration workshop – identified 100+ new integration projects
- ✓ Developed end-state operating model and organization design recommendations

Upcoming Activities

- ➢ Teams to continue to develop integration roadmap across people, process and system requirements
- ➢ Implement organization changes
- ➢ Launch brand expression changes for the combined business
- ➢ Set metrics and accountability for go-to-market strategies across markets
- ➢ Manage change to minimize disruption to employees, customers, and other stakeholders

© QuidelOrtho 2022

Multiple Product-Based Growth Drivers

Savanna

Fully integrated, rapid multiplex molecular system

- Easy-to-use, with one of the fastest turnaround times and a small footprint utilizing a cost-effective mini-panel concept
- Investing to secure global regulatory clearances and penetrating the high-growth molecular diagnostic market
- System has strong appeal in Ortho's small-to-medium sized hospital customers



Savanna®

Sofia

Point-of-Care system that is uniquely positioned for the decentralization of testing

- Revenue pull-through opportunity created by the expanded 80K installed base (up 38K or ~90% since 4Q19)
- Menu expansion to include respiratory virus panel, c. difficile and other gastrointestinal assays
- Opportunity for expansion into retail and at-home markets



Sofia®

Triage

Cost-effective, easy-to-use instrument for cardiovascular and toxicology diagnostic assays that is used in hospital POC settings

- Significant OUS opportunities that are expected to be much of the near-term cross-selling revenue synergies
- New assays (TriageTrue hsTroponin; Triage PLGF) are expected to accelerate growth



Triage®

Integrated Clinical Lab Analyzer Systems

Higher throughput analyzers that have been driving Ortho's improved growth profile

- Installed base has been growing at double-digits with a long runway to go
- Pulls through both clinical chemistry and higher margin immunoassay consumable revenue
- Refreshed VITROS® 5600 Integrated System is expected early next year



VITROS 5600



VITROS® XT 7600 Integrated System

Commercial Excellence Program Drives Commercial Success

Market Specific & Globally Connected

Market Specific & Globally Connected ····· Insight Driven ····· Focused & Disciplined ····· Digitally Enabled



Commercial Edge

- Define sweet spot through market and customer segmentation
- Establish growth equation
- Focused commercial KPIs that drive strategy effectiveness
- Expand customer facing resources (i.e. laboratory specialists)

Commercial Evolution

- Increase sales efficiency through strategy optimization
- Introduce and align new customer engagement channels (non sales)
- Identify additional growth opportunities

Commercial 360

- Enhance customer value by digitally aligning and integrating customer touchpoints
- Optimize customer engagement channels to accelerate revenue
- Expand market reach

© QuidelOrtho 2022

Award Winning Service Organization

#1 for 7 Years in a Row in the IMV ServiceTrak™ Integrated System

	Ortho	Competitor A	Competitor B	Competitor C	Competitor D
NPS	1	5	3	4	2
Manufacturer Performance	1	4	2	3	5
System Performance	1	5	2	5	3
Service Performance	2	5	1	3	4
Phone Support	1	5	3	2	4
Field Engineer Performance	2	4	1	5	3
Lab Specialist Performance	1	3	4	5	2
Training Performance	1	5	3	4	2

IMV Service Trak™ is a 3rd party blinded study (n = 880), U.S. Clinical Laboratory customers only.

2022 — **Ortho Care® Program**
United States #1 Customer Satisfaction



2022 — **Ortho Clinical Diagnostics**
China Medical Device #1 Service



2022 — **Ortho Clinical Diagnostics**
India Best Healthcare Brands

2022 — **Ortho Care® Program**
Global Customer Service Dept of the Year



2021 — **Ortho Care® Program**
Voted #1 Global Customer Service Dept



2021 — **Ortho Products and Platforms**
Global Product Innovation Awards



2019 — **Ortho Care® Program**
Philippines Customer Service Excellence



2020 — **Ortho Care® Program**
India Excellence in Service



© QuidelOrtho 2022

Operational Excellence: Cost Synergies Are Well Underway

- We believe we are on track to deliver $30M of our targeted $90M cost synergies in 2023
- Competitively bidding insurance and audit fees, technology agreements, and indirect sourcing consolidation, and eliminating duplicate costs
- This doesn't include the $45 million in annual interest expense savings that we have also secured



Capital Deployment

Strong Balance Sheet and Cash Generation Give Us the Flexibility to Allocate Funds Toward Several Capital Deployment Priorities

Support menu expansion and development of innovative new instruments	R&D Investment
Capital investment to increase manufacturing capacity	Manufacturing Capacity Expansion
Maintain appropriate levels of leverage	Debt Paydown
Return capital to shareholders through share repurchases is under consideration	Share Repurchase
Strategic M&A as the right opportunities present themselves	Strategic M&A

FINANCIAL RESULTS

© QuidelOrtho 2022

2Q 2022 Supplemental Combined Revenue Results[1]



Revenue by Business Unit

POC +181% [+19% ex-COVID-19]
Labs[2] +3% [+6% ex-COVID-19]
TM +9% [+9% ex-COVID-19]
MDx (40%) [+45% ex-COVID-19]

- **Point-of-Care (POC)** growth driven by COVID-19 and pull-through of our respiratory menu
- **Labs** growth driven by strength in clinical chemistry and non-COVID-19 immunoassay
- **Transfusion Medicine (TM)** growth driven by strength in Donor Screening, notably plasma
- **Molecular Diagnostics (MDx)** growth, ex-COVID-19, driven by Lyra, Savanna, and Solana



Revenue by Geography

North America +59% [+16% ex-COVID-19]
EMEA +6% [+8% ex-COVID-19]
China +25% [(10%) ex-COVID-19]
Other[3] +2% [+5% ex-COVID-19]

- **North America** growth driven by POC, Labs, and TM
- **EMEA** delivered strong growth in Labs
- **China** growth driven by Labs and COVID-19 within POC
- **Other regions[3]** saw broad-based TM strength, and to a lesser extent growth in Labs



Revenue by Category

Recurring +1% [+9% ex-COVID-19]
QuickVue +756%
Instrument +2%

- **Recurring revenue** growth driven by across-the-board strength excluding COVID-19 revenues
- **Instrument revenue** improved from first quarter 2022, but continues to be soft due to supply chain challenges
- **QuickVue revenue** strength driven by COVID-19; Government contract was completed

1. All dollar amounts are in millions. includes presentation of supplemental second quarter 2022 and 2021 revenues and adjusted operating results as if Quidel and Ortho had been combined for the applicable periods. Revenue growth rates are shown on a constant currency basis; the term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using internally derived currency exchange rates held constant for each period; this additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.
2. Labs includes legacy Ortho Clinical Labs and non-core revenue, as well as legacy Quidel Specialized Diagnostic Solutions business
3. Other regions include Latin America, Japan and other Asia-Pacific markets

Supplemental Combined Operating Results Summary[1]

Solid Results Demonstrate Resiliency of the Combined Business Model

2Q 2022 Highlights

- Adjusted Gross Profit Margin of 53.6% is up 80-basis points
- Adjusted Diluted EPS grew 123% to $2.12
- Adjusted EBITDA grew approximately 75% to $291M, representing an Adjusted EBITDA margin of 32.4%

	Fiscal Quarter Ended	
	2Q22	**2Q21**
Total Revenue	**$898.5**	**$669.1**
Constant Currency Growth	37.5%	-
Adjusted Gross Profit	$481.7	$353.3
Adjusted Gross Profit Margin	53.6%	52.8%
Adjusted Diluted EPS	$2.12	$0.95
Adjusted Diluted EPS Growth	123%	-
Adjusted EBITDA	$290.8	$165.9
Adjusted EBITDA Margin	32.4%	24.8%

Unless otherwise noted, dollars and growth rates are at actual foreign exchange rates
1. The term "constant currency" means we have translated local currency revenues for all reporting periods into U.S. dollars using the same comparable foreign currency exchange rates. Includes presentation of supplemental second quarter 2022 and 2021 revenues and adjusted operating results as if Quidel and Ortho had been combined for the applicable periods. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.
2. Reference non-GAAP reconciliation slide for reconciliation to closest GAAP metric

Strong Cash Flow and Balance Sheet[1]

2Q22 Cash Flow

$225M
Operating Cash Flow[2]

$26M
Capital Expenditures[2]

$279M
Recurring
Free Cash Flow[3]

2Q22 Balance Sheet

$447M
Cash &
Marketable Securities

$2.7B
Total Debt

~1.1x
Net Debt to
Adjusted EBITDA[4]

1. As of 2Q22 and 12 months ended 2Q22
2. 2Q22 GAAP cash flows
3. Management estimate of recurring free cash flow reflecting operating cash flow less capex and $80 million in acquisition costs
4. Based on management estimates for trailing 12 months supplemental combined EBITDA and 2Q22 net debt

© QuidelOrtho 2022

FY 2022 Supplemental Combined Guidance

$2.49 – 2.57 Billion (+6% – 9% constant currency)
Total Revenue, Ex-COVID-19

$1.29 – 1.34 Billion
COVID-19 Revenue

$200 – 260 Million
Flu and ABC Combo Revenue[1]

$3.78 – 3.91 Billion (+3% – 5% constant currency)
Total Revenue

150 bps
Currency Translation Headwind to Sales

$1.38 – $1.45 Billion (36.5% – 37% margin)
Adjusted EBITDA

$11.80 – $12.75
Adjusted Diluted EPS

$118 – $123 Million
Net Interest Expense

~25%
Tax Rate

~68 Million
Share Count

Key Assumptions

- If there is a heavy 4Q flu season in North America, it could move revenue towards the high end of our guidance range
- If COVID-19 variants lead to a significant outbreak and a consequential pick-up in COVID testing, it could move revenue toward the high end of the guidance range
- We are not including a large government order for COVID-19 tests in our guidance

1. ABC Combo includes Flu A/B and COVID-19

Summary



A strong quarter across our commercial, corporate, and cultural metrics



Expecting 6% - 9% growth, ex-COVID-19 revenues, in FY 2022, as we focus on base business execution, while expecting to accelerate and exceed cost and revenue synergy targets



Enthusiastic embrace of collaboration, cross-selling, and customer care across our expanded global footprint points to better-than-expected opportunities to increase market share, improve margins and deliver shareholder value

© QuidelOrtho 2022

APPENDIX

© QuidelOrtho 2022

Q2 2022 Supplemental Combined Income Statement

	QuidelOrtho As Reported	Pre-combination Ortho results [(a)]	Supplemental combined results
Total revenues	$ 613.4	$ 285.1	$ 898.5
Cost of sales, excluding amortization of intangibles	275.9	153.0	428.9
Selling, marketing and administrative	118.4	79.1	197.5
Research and development	34.2	19.9	54.1
Amortization of intangible assets	21.0	21.7	42.7
Acquisition and integration costs	80.2	56.7	136.9
Other operating expenses	4.0	0.6	4.6
Operating income (loss)	79.7	(45.9)	33.8
Interest expense, net	10.3	20.3	30.6
Loss on extinguishment of debt	24.0	—	24.0
Other expense (income), net	2.5	(6.7)	(4.2)
Income (loss) before provision for income taxes	42.9	(59.5)	(16.6)
Provision for income taxes	23.6	1.2	24.8
Net income (loss)	$ 19.3	$ (60.7)	$ (41.4)

(a) Pre-combination results include Ortho's results of operations from April 4, 2022 through May 27, 2022.

Q2 2022 Supplemental Combined Non-GAAP Reconciliation

	Gross profit	Selling, marketing and adiministrative	Research and development	Operating income	Operating income margin	Interest expense, net	Other income, net	Provision for income taxes	Net (loss) income
Supplemental combined	$ 450.6	$ 221.2	$ 54.1	$ 33.8	3.8%	$ 30.6	$ (4.2)	$ 24.8	$ (41.4)
Adjustments:									
Amortization of intangibles	19.0	(23.7)	—	42.7		—	—	—	42.7
Pre-IPO legacy stock based compensation	0.1	(1.3)	—	1.4		—	—	—	1.4
Acquisition and integration costs	—	—	—	136.9		—	—	—	136.9
Loss on extinguishment of debt	—	—	—	—		—	—	—	24.0
Unwind inventory fair value adjustment	11.2	—	—	11.2		—	—	—	11.2
Noncash interest expense for deferred consideration	—	—	—	—		(0.8)	—	—	0.8
Amortization of deferred cloud computing implementation costs	0.4	(1.3)	—	1.7		—	—	—	1.7
Derivative mark-to-market gain	—	—	—	—		—	0.3	—	(0.3)
Loss on investments	—	—	—	—		—	(0.8)	—	0.8
Employee compensation charges and other costs	0.4	(0.4)	(0.3)	1.1		—	—	—	1.1
EU medical device regulation transition costs	—	—	(1.0)	1.0		—	—	—	1.0
Change in fair value of acquisition contingencies	—	(0.1)	—	0.1		—	—	—	0.1
Other adjustments	—	(0.3)	—	1.1		(0.5)	—	—	1.6
Income tax impact of adjustments	—	—	—	—		—	—	37.7	(37.7)
Supplemental combined, as adjusted	**$ 481.7**	**$ 194.1**	**$ 52.8**	**$ 231.0**	**25.7%**	**$ 29.3**	**$ (4.7)**	**$ 62.5**	**$ 143.9**

Pro Forma Revenue by Region, Business Unit, and Category

Segment revenue	Fiscal Quarter Ended July 3, 2022	Fiscal Quarter Ended July 4, 2021	Percent Change	Currency Impact	Constant Currency [a]	Less: COVID-19 revenue impact	Constant Currency [a] ex COVID-19 revenue
North America	$ 595.7	$ 375.3	58.7%	(0.2)%	58.9%	(43.2)%	15.7 %
EMEA	82.9	85.7	(3.3)%	(9.0)%	5.7%	2.0%	7.7 %
China	96.1	78.7	22.1%	(3.2)%	25.3%	(34.9)%	(9.6)%
Other	123.8	129.4	(4.3)%	(6.5)%	2.2%	2.5%	4.7%
Supplemental Combined Total Revenue	$ 898.5	$ 669.1	34.3%	(3.2)%	37.5%	(28.5)%	9.0 %

	Fiscal Quarter Ended July 3, 2022	Fiscal Quarter Ended July 4, 2021	Percent Change	Currency Impact	Constant Currency [a]
Point-Of-Care	$ 367.0	$ 131.7	178.7%	(1.8)%	180.5%
Labs	$ 342.0	$ 340.5	0.4%	(2.7)%	3.1%
Transfusion Medicine	168.8	162.4	3.9%	(5.0)%	8.9%
Molecular Diagnostics	20.7	34.5	(40.0)%	(0.4)%	(39.6)%
Supplemental Combined Total Revenue	$ 898.5	$ 669.1	34.3%	(3.2)%	37.5%

	Fiscal Quarter Ended July 3, 2022	Fiscal Quarter Ended July 4, 2021	Percent Change	Currency Impact	Constant Currency [a]
Recurring Revenues	$ 585.5	$ 597.3	(2.0)%	(3.0)%	1.0%
QuickVue Revenues	$ 273.6	$ 32.0	755.0%	(1.2)%	756.2%
Instrument Revenues	39.4	39.8	(1.0)%	(2.8)%	1.8%
Supplemental Combined Total Revenue	$ 898.5	$ 669.1	34.3%	(3.2)%	37.5%

(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using internally derived currency exchange rates held constant for each period; this additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information

Supplemental Combined Adjusted EBITDA Reconciliation

$ millions	Fiscal Quarter	
	Q2 2022	Q2 2021
Supplemental combined net loss	$(41.4)	$(0.9)
Interest expense, net	30.6	34.4
Provision for income taxes	24.8	17.7
Depreciation and amortization	97.9	95.4
Pre-IPO legacy stock-based compensation	1.4	11.0
Employee compensation charges and other costs	1.1	1.7
Loss on extinguishment of debt	24.0	—
Acquisition and integration-related costs	136.9	1.1
Unwind inventory fair value adjustment	11.2	—
EU medical device regulation transition costs	1.0	0.9
Loss on other investments	0.8	0.2
Amortization of deferred cloud computing implementation costs	1.7	1.2
Change in fair value of contingent consideration	0.1	0.1
Derivative mark-to-market gain	(0.3)	1.0
Other adjustments	1.0	2.1
Supplemental combined Adjusted EBITDA	$290.8	$165.9

Unless otherwise noted, dollars are at actual foreign exchange rates.

Pro Forma Net Income and Adjusted EBITDA include the results of historical Quidel and Ortho and do not include any pro forma adjustments required under Regulation S-X Article 11 or ASC 805.

QuidelOrtho™

THANK YOU